Targeting eosinophils in respiratory diseases: Biological axis, emerging therapeutics and treatment modalities.

Lee, L-Y; Hew, GSY; Meenu,; Shukla, SD; Satija, S; Khurana, N; Anand, K; Dureja, H; Singh, SK; Mishra, V; Singh, PK; Gulati, M; Prasher, P; Aljabali, AAA; Tambuwala, MM; Thangavelu, L; Panneerselvam, J; Gupta, G; Zacconi, FC; Shastri, M; Jha, NK; Xenaki, D; MacLoughlin, R; Oliver, BG; Chellappan, DK; Dua, K

Targeting eosinophils in respiratory diseases: Biological axis, emerging therapeutics and treatment modalities.

Lee, L-Y Hew, GSY Meenu, Shukla, SD Satija, S

Khurana, N Anand, K Dureja, H Singh, SK Mishra, V Singh, PK Gulati, M Prasher, P Aljabali, AAA Tambuwala, MM Thangavelu, L Panneerselvam, J Gupta, G Zacconi, FC Shastri, M Jha, NK Xenaki, D MacLoughlin, R Oliver, BG Chellappan, DK Dua, K

Permalink

Publisher:: Elsevier
Publication Type:: Journal Article
Citation:: Life Sciences, 2021, 267
Issue Date:: 2021-02

Closed Access

	Filename	Description	Size
	1-s2.0-S0024320520317331-main.pdf		2.21 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Lee, L-Y
dc.contributor.author	Hew, GSY
dc.contributor.author	Meenu,
dc.contributor.author	Shukla, SD
dc.contributor.author	Satija, S https://orcid.org/0000-0003-4702-6534
dc.contributor.author	Khurana, N
dc.contributor.author	Anand, K
dc.contributor.author	Dureja, H
dc.contributor.author	Singh, SK
dc.contributor.author	Mishra, V
dc.contributor.author	Singh, PK
dc.contributor.author	Gulati, M
dc.contributor.author	Prasher, P
dc.contributor.author	Aljabali, AAA
dc.contributor.author	Tambuwala, MM
dc.contributor.author	Thangavelu, L
dc.contributor.author	Panneerselvam, J
dc.contributor.author	Gupta, G
dc.contributor.author	Zacconi, FC
dc.contributor.author	Shastri, M
dc.contributor.author	Jha, NK
dc.contributor.author	Xenaki, D
dc.contributor.author	MacLoughlin, R
dc.contributor.author	Oliver, BG
dc.contributor.author	Chellappan, DK
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159
dc.date.accessioned	2021-11-19T02:37:15Z
dc.date.available	2020-12-23
dc.date.available	2021-11-19T02:37:15Z
dc.date.issued	2021-02
dc.identifier.citation	Life Sciences, 2021, 267
dc.identifier.issn	0024-3205
dc.identifier.issn	1879-0631
dc.identifier.uri	http://hdl.handle.net/10453/151729
dc.description.abstract	Eosinophils are bi-lobed, multi-functional innate immune cells with diverse cell surface receptors that regulate local immune and inflammatory responses. Several inflammatory and infectious diseases are triggered with their build up in the blood and tissues. The mobilization of eosinophils into the lungs is regulated by a cascade of processes guided by Th2 cytokine generating T-cells. Recruitment of eosinophils essentially leads to a characteristic immune response followed by airway hyperresponsiveness and remodeling, which are hallmarks of chronic respiratory diseases. By analysing the dynamic interactions of eosinophils with their extracellular environment, which also involve signaling molecules and tissues, various therapies have been invented and developed to target respiratory diseases. Having entered clinical testing, several eosinophil targeting therapeutic agents have shown much promise and have further bridged the gap between theory and practice. Moreover, researchers now have a clearer understanding of the roles and mechanisms of eosinophils. These factors have successfully assisted molecular biologists to block specific pathways in the growth, migration and activation of eosinophils. The primary purpose of this review is to provide an overview of the eosinophil biology with a special emphasis on potential pharmacotherapeutic targets. The review also summarizes promising eosinophil-targeting agents, along with their mechanisms and rationale for use, including those in developmental pipeline, in clinical trials, or approved for other respiratory disorders.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	Elsevier
dc.relation	The Rebecca L Cooper Medical Research Foundation L
dc.relation.ispartof	Life Sciences
dc.relation.isbasedon	10.1016/j.lfs.2020.118973
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	0601 Biochemistry and Cell Biology, 1115 Pharmacology and Pharmaceutical Sciences
dc.subject.classification	Pharmacology & Pharmacy
dc.subject.mesh	Animals
dc.subject.mesh	Cytokines
dc.subject.mesh	Eosinophils
dc.subject.mesh	Humans
dc.subject.mesh	Lung
dc.subject.mesh	Respiration Disorders
dc.subject.mesh	Respiratory Tract Diseases
dc.subject.mesh	Th2 Cells
dc.subject.mesh	Lung
dc.subject.mesh	Eosinophils
dc.subject.mesh	Th2 Cells
dc.subject.mesh	Animals
dc.subject.mesh	Humans
dc.subject.mesh	Respiratory Tract Diseases
dc.subject.mesh	Respiration Disorders
dc.subject.mesh	Cytokines
dc.subject.mesh	Animals
dc.subject.mesh	Cytokines
dc.subject.mesh	Eosinophils
dc.subject.mesh	Humans
dc.subject.mesh	Lung
dc.subject.mesh	Respiration Disorders
dc.subject.mesh	Respiratory Tract Diseases
dc.subject.mesh	Th2 Cells
dc.title	Targeting eosinophils in respiratory diseases: Biological axis, emerging therapeutics and treatment modalities.
dc.type	Journal Article
utslib.citation.volume	267
utslib.location.activity	Netherlands
utslib.for	0601 Biochemistry and Cell Biology
utslib.for	1115 Pharmacology and Pharmaceutical Sciences
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Strength - CHT - Health Technologies
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Life Sciences
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health/GSH.Pharmacy
pubs.organisational-group	/University of Technology Sydney/Centre for Health Technologies (CHT)
utslib.copyright.status	closed_access	*
pubs.consider-herdc	false
dc.date.updated	2021-11-19T02:37:12Z
pubs.publication-status	Published
pubs.volume	267

Abstract:

Eosinophils are bi-lobed, multi-functional innate immune cells with diverse cell surface receptors that regulate local immune and inflammatory responses. Several inflammatory and infectious diseases are triggered with their build up in the blood and tissues. The mobilization of eosinophils into the lungs is regulated by a cascade of processes guided by Th2 cytokine generating T-cells. Recruitment of eosinophils essentially leads to a characteristic immune response followed by airway hyperresponsiveness and remodeling, which are hallmarks of chronic respiratory diseases. By analysing the dynamic interactions of eosinophils with their extracellular environment, which also involve signaling molecules and tissues, various therapies have been invented and developed to target respiratory diseases. Having entered clinical testing, several eosinophil targeting therapeutic agents have shown much promise and have further bridged the gap between theory and practice. Moreover, researchers now have a clearer understanding of the roles and mechanisms of eosinophils. These factors have successfully assisted molecular biologists to block specific pathways in the growth, migration and activation of eosinophils. The primary purpose of this review is to provide an overview of the eosinophil biology with a special emphasis on potential pharmacotherapeutic targets. The review also summarizes promising eosinophil-targeting agents, along with their mechanisms and rationale for use, including those in developmental pipeline, in clinical trials, or approved for other respiratory disorders.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/151729